Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine

Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine

Stock Markets15 minutes ago (Oct 13, 2021 08:16PM ET)

(C) Reuters. FILE PHOTO: Vials labelled “Astra Zeneca COVID-19 Coronavirus Vaccine” and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/File Photo

(Reuters) – Australian biotech CSL (OTC:CSLLY) said on Thursday it was committed to its agreement for the production of about 50 million doses of AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine into 2022.

The announcement came after a media report said the British drugmaker’s vaccine, Vaxzevria, will no longer be manufactured in Australia due to demand for vaccines of Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). [nL4N2R91XR]

Pfizer and Moderna have established a market dominance by using mRNA-based COVID-19 vaccine technology to fight the pandemic.

CSL, in a brief statement, added that more than 20 million of the doses have already been produced, and it is expected that the remaining production will be completed early next year.

Cafes, gyms and restaurants in Sydney welcomed back fully vaccinated customers earlier this week after nearly four months of a lockdown, as Australia aims to begin living with the coronavirus and gradually reopen with high rates of inoculation.

Australia’s CSL reaffirms commitment to making AstraZeneca COVID vaccine

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!